Hikma Pharmaceuticals Stock
Hikma Pharmaceuticals Stock
The Hikma Pharmaceuticals stock is trending slightly upwards today, with an increase of €0.17 (0.890%) compared to yesterday's price.
Pros and Cons of Hikma Pharmaceuticals in the next few years
Pros
?
G***** c******* t* c**********
?
B****
?
C******** o* t** e**********
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Hikma Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Hikma Pharmaceuticals | 0.890% | 5.476% | 4.902% | -7.404% | 9.432% | -22.960% | -35.369% |
| Viatris Inc. | 0.550% | -1.155% | -1.764% | 52.843% | 33.213% | 36.677% | 10.713% |
| Opko Health Inc. | 0.840% | 4.348% | 13.208% | 7.354% | 10.072% | -22.780% | -60.027% |
| China Traditional Chinese Medicine Co Ltd | - | 0.000% | 0.000% | -5.983% | 0.917% | -37.500% | -50.893% |
Comments
Hikma Pharmaceuticals (HKMPF) had its "buy" rating reaffirmed by Citigroup Inc..
Show more
Ratings data for HKMPF provided by MarketBeat
Hikma Pharmaceuticals (OTCMKTS:HKMPF) was downgraded by analysts at Barclays PLC to an "underweight" rating.
Show more
Ratings data for HKMPF provided by MarketBeat
Hikma Pharmaceuticals PLC (OTCMKTS: HKMPF) is now covered by analysts at BNP Paribas. They set an "outperform" rating on the stock.
Show more
Ratings data for HKMPF provided by MarketBeat